New pill for macular degeneration enters first human tests
NCT ID NCT07330674
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The main goal is to check safety and how the body processes the drug. About 68 participants will take either ABF-101 or a placebo to see if it is well-tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABF-101 (oral drug)
What this could lead to
If this early trial shows ABF-101 is safe, it could lead to a new oral treatment option for age-related macular degeneration.
What could go wrong
This is a very early Phase 1 study with only 68 participants, focused on safety. It is too soon to know if ABF-101 will effectively treat AMD or have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE RELATED MACULAR DEGENERATION (ARMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dallas Clinical Research Unit
RECRUITINGDallas, Texas, 75247, United States
Contact